KREJČÍ, Pavel. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. New England Journal of Medicine. Waltham: Massachussetts Medical Society, 2019, vol. 381, No 13, p. 1291. ISSN 0028-4793. Available from: https://dx.doi.org/10.1056/NEJMc1910394.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia
Authors KREJČÍ, Pavel (203 Czech Republic, guarantor, belonging to the institution).
Edition New England Journal of Medicine, Waltham, Massachussetts Medical Society, 2019, 0028-4793.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10608 Biochemistry and molecular biology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 74.699
RIV identification code RIV/00216224:14110/19:00112475
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1056/NEJMc1910394
UT WoS 000489333500020
Keywords in English Achondroplasia; C-type natriuretic peptide
Tags 14110513, rivok
Tags International impact
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 4/3/2020 14:30.
Abstract
Savarirayan et al. (July 4 issue)1 report increased skeletal growth in patients with achondroplasia (a common type of dwarfism caused by activating mutations in the tyrosine kinase fibroblast growth factor receptor 3 gene FGFR3) who received vosoritide, a stable analogue of C-type natriuretic peptide. Their study is a breakthrough in treatment for achondroplasia, and it offers an intriguing possibility of broader clinical applications.
Links
MUNI/A/1087/2018, interní kód MUName: Molekulární a buněčná biologie pro biomedicínské vědy
Investor: Masaryk University, Category A
PrintDisplayed: 20/7/2024 08:24